← Organogenesis Holdings Inc. (ORGO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Organogenesis Holdings Inc. (ORGO)
Pharmaceutical Preparations · market cap $184M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Organogenesis Holdings (ORGO) is a commercial-stage regenerative medicine company with $564M in 2025 revenue, operating primarily in wound care and tissue regeneration. Its lead pipeline asset is an Amniotic Suspension Allograft in Phase 3 development for Knee Osteoarthritis, and the next scheduled event is an August 6, 2026 earnings release. The company carries no net debt ($91.4M cash), but faces elevated dilution risk and a 9.5% short float.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Amniotic Suspension Allograft | Phase 3 | Knee Osteoarthritis |
Price & technical context
3-month
-40.7%
6-month
-39.4%
12-month
-66.8%
52-wk range
$1.36–$6.54
vs 50-day MA
-22.0%
vs 200-day MA
-49.5%
Realized vol
73.3%
Max drawdown
-79.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ORGO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.